LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Gain Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERGANX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / GANX COVERAGE

What’s moving Gain Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Investors are testing whether Gain Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

The development tests whether Gain Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development

Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development

The development tests whether Gain Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
04
Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease

Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease

The development tests whether Gain Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest GANX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-16 · Period 2026-07-16SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-29SEC ↗8-KMaterial company eventFiled 2026-06-25 · Period 2026-06-24SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-28 · Period 2026-06-24SEC ↗4Official SEC filingFiled 2026-07-17 · Period 2026-07-15SEC ↗
EARNINGS / QUARTERLY TRACKER

Gain Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.